AbbVie and Google spinout invest $1 billion to combat aging

27 June 2018
2019_biotech_test_vial_discovery_big

Illinois, USA-based pharma major AbbVie (NYSE: ABBV) has renewed its partnership with Calico, the Alphabet (Nasdaq: GOOG) subsidiary dedicated to combating the effects of aging.

The announcement comes as the two companies make a combined $1 billion investment in their collaborative efforts to treat aging-related diseases including neurodegeneration and cancer.

The Google spinout, founded in 2013, has never announced any novel therapies or technologies and is notoriously secretive, releasing only 17 press releases since its founding.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology